SAR402663
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2025
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
(GlobeNewswire)
- "Sanofi is currently evaluating SAR402663 in a phase 1/2 (clinical study identifier: NCT06660667), for the treatment of patients with neovascular AMD."
Fast track • Wet Age-related Macular Degeneration
1 to 1
Of
1
Go to page
1